RadioPharm Theranostics

RadioPharm Theranostics is a clinical-stage radiotherapeutics company focused on developing innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas with high unmet medical needs. The company's platform comprises four distinct and highly differentiated technologies spanning peptides, small molecules, and monoclonal antibodies for use in various cancers. As of March 2023, RadioPharm's clinical program included five Phase II and two Phase I trials targeting solid tumor cancers such as breast, kidney, and brain.

In September 2022, RadioPharm entered a joint venture with The University of Texas MD Anderson Cancer Center, called RadioPharm Ventures, to develop novel radiopharmaceutical therapeutic products for cancer. The joint venture aims to advance at least four therapeutic candidates based on MD Anderson's intellectual property, including a humanized immunoglobulin G (IgG) antibody against the tumor-specific antigen B7-H3. This antibody exhibited efficacy in eliminating resistant colorectal cancers in preclinical studies.

In March 2023, RadioPharm acquired Pharma15 Corporation, a private US-based venture developing next-generation therapeutic radiopharmaceuticals for prostate cancer. The acquisition aimed to secure technologies targeting receptors expressed on cancer cells but not in healthy tissues, potentially overcoming resistance to currently available prostate-specific membrane antigen (PSMA) targeting cancer therapies.

In June 2024, RadioPharm secured commitments to raise USD 70 million from leading international and Australian institutional investors to advance its clinical programs. The company also entered agreements with Lantheus Holdings, including a USD 7.5 million equity investment and an option for an additional USD 7.5 million within six months. RadioPharm assigned and sub-licensed two preclinical assets to Lantheus for USD 3 million.